Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in advanced nasopharyngeal carcinoma
NCT02328261Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of icotinib in nasopharyngeal carcinoma (NPC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02328261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328261.